|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-12-6
|
|
pubmed:abstractText |
Terameprocol (M4N, EM-1421) is a novel transcription inhibitor that selectively interferes with HPV viral genes E6/E7 with Sp1-dependent promoters, and induces apoptosis by inactivation of the CDC2/cyclin B complex (maturation promoting factor) and production and phosphorylation of survivin. This trial was designed to define the maximum tolerated dose (MTD), dose-limiting toxicity and determine the pharmacokinetic profiles of intravaginal terameprocol in women with HPV-linked cervical squamous intraepithelial neoplasia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/BIRC5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CDC2-CDC28 Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Microtubule-Associated Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nordihydroguaiaretic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Ointments,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/terameprocol
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
554-62
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17905420-Adolescent,
pubmed-meshheading:17905420-Adult,
pubmed-meshheading:17905420-CDC2-CDC28 Kinases,
pubmed-meshheading:17905420-Cervical Intraepithelial Neoplasia,
pubmed-meshheading:17905420-Dose-Response Relationship, Drug,
pubmed-meshheading:17905420-Female,
pubmed-meshheading:17905420-Humans,
pubmed-meshheading:17905420-Immunohistochemistry,
pubmed-meshheading:17905420-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:17905420-Microtubule-Associated Proteins,
pubmed-meshheading:17905420-Neoplasm Proteins,
pubmed-meshheading:17905420-Neoplasm Staging,
pubmed-meshheading:17905420-Nordihydroguaiaretic Acid,
pubmed-meshheading:17905420-Ointments,
pubmed-meshheading:17905420-Papillomaviridae,
pubmed-meshheading:17905420-Papillomavirus Infections,
pubmed-meshheading:17905420-Tumor Markers, Biological,
pubmed-meshheading:17905420-Uterine Cervical Neoplasms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase I/II clinical safety studies of terameprocol vaginal ointment.
|
|
pubmed:affiliation |
Department of Family and Community Medicine, and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. nkhanna@som.umaryland.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
